Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) SEC filings page on Stock Titan provides access to the company’s public filings and related disclosures as they appear in the U.S. Securities and Exchange Commission’s EDGAR system. Mirum is a biopharmaceutical and rare disease company with approved therapies such as LIVMARLI, CHOLBAM and CTEXLI and a pipeline that includes volixibat, brelovitug and MRM-3379, as described in its press releases.
Through this page, users can review Mirum’s current and historical filings, including Form 8-K reports that describe material events. Recent 8-K filings have covered topics such as an Agreement and Plan of Merger and Reorganization to acquire Bluejay Therapeutics, associated private placement subscription agreements, and corporate updates on financial results. Other 8-K disclosures include receipt of a Paragraph IV Certification Notice Letter related to a generic version of LIVMARLI and press releases furnished as exhibits discussing quarterly results.
Stock Titan enhances these documents with AI-powered summaries designed to highlight the main points of lengthy filings. For example, AI summaries can help readers quickly understand key terms of merger agreements, private placement structures, or the implications of patent-related notices referenced in Mirum’s 8-Ks. Users can also monitor unregistered sales of equity securities and other capital markets activities described in the filings.
This page updates as new Mirum filings are posted to EDGAR, giving investors and researchers a structured way to follow regulatory disclosures alongside the company’s rare disease commercial and development programs. Forms such as 10-K, 10-Q and additional 8-Ks, when available, can be reviewed with AI-generated insights to assist in interpreting Mirum’s reporting.
Mirum Pharmaceuticals director Patrick J. Heron reported indirect fund activity in Mirum stock. On January 23, 2026, Frazier Life Sciences X, L.P., an investment fund associated with him, received 159,277 shares of Mirum common stock in connection with the merger of Bluejay Therapeutics into Mirum, when Mirum’s closing share price was $94.29. That same day, Frazier Life Sciences X, L.P. also purchased 131,425 shares of Mirum common stock at $68.48 per share.
After these transactions, Frazier Life Sciences X, L.P. held 459,010 Mirum shares indirectly reported by Heron, and Frazier Life Sciences IX, L.P. held 3,566,912 shares. Heron also reported 5,703 Mirum shares held directly in his own name. The footnotes state that the Frazier funds hold the shares directly and that Heron disclaims beneficial ownership of those fund-held securities except to the extent of his pecuniary interest.
Frazier Life Sciences-affiliated funds and managers have updated their ownership disclosures in Mirum Pharmaceuticals, Inc. (MIRM) through Amendment No. 8 to a Schedule 13D. The filing shows Frazier Life Sciences IX, L.P. holding 3,566,912 shares of common stock, representing 5.9% of the class, and Frazier Life Sciences X, L.P. holding 459,010 shares, or 0.8%. Frazier Life Sciences Public Fund, L.P. holds 2,514,947 shares, or 4.2%, while other Frazier funds hold smaller stakes.
The filing attributes 4,025,922 shares, or 6.7% of the class, to James N. Topper through shared voting and investment power over certain funds, and 4,108,404 shares, or 6.8%, to Patrick J. Heron, including 76,779 option shares. The investors state the shares were acquired for investment purposes and that they have no present plans for mergers, control changes, or other major corporate actions. A registration rights agreement dated December 7, 2025 entitles several Frazier funds to have Mirum register for resale both their common shares and shares underlying pre-funded warrants purchased on January 23, 2026, including warrants held by the public fund subject to a 9.99% beneficial ownership cap.
Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, using a mix of cash, stock and potential future milestone payments. At closing, Mirum acquired Bluejay’s net cash of approximately $56.6 million and agreed to pay Target security holders up to $280.8 million in cash and 4,673,597 shares of Mirum common stock as upfront consideration, plus up to $25.8 million in cash and 522,375 shares as holdback consideration. The deal also includes up to $200 million in cash milestone payments tied to net sales. Following the mergers and related private placements, 59,879,958 shares of Mirum common stock were issued and outstanding as of January 23, 2026. Certain funds affiliated with Frazier Life Sciences, linked to a Mirum director and owning more than five percent of Mirum’s stock, participated as Bluejay security holders and will receive their pro rata share of the merger consideration.
Mirum Pharmaceuticals senior vice president and global controller Jolanda Howe reported equity transactions tied to the vesting of restricted stock units. On January 21, 2026, 1,542 restricted stock units were converted into the same number of common shares at an exercise price of $0, reflecting the scheduled vesting of her award. On January 22, 2026, 926 common shares were sold at an average price of $93.3252 to cover tax withholding obligations related to this vesting. After these transactions, Howe directly held 3,042 shares of common stock and 3,083 restricted stock units, which continue to vest in equal annual installments through the third anniversary of January 21, 2025.
Mirum Pharmaceuticals chief medical officer Joanne Quan reported routine equity compensation activity and a related stock sale. On January 21, 2026, 3,334 restricted stock units vested and were converted into the same number of Mirum common shares, increasing her directly held stake to 14,639 shares. The filing notes that each restricted stock unit represents a right to receive one share of common stock or its cash equivalent at the issuer’s discretion.
On January 22, 2026, Quan sold 1,822 shares of common stock at an average price of $93.3252 per share to cover tax withholding obligations tied to the vesting. After these transactions, she directly owned 12,817 shares of Mirum common stock and held 6,666 restricted stock units, which are scheduled to vest in equal thirds on each anniversary of January 21, 2025 until fully vested after three years.
Mirum Pharmaceuticals' chief financial officer Eric Bjerkholt reported routine equity compensation activity. On January 21, 2026, 3,334 restricted stock units were converted into the same number of common shares at an exercise price of $0, increasing his directly held common stock to 43,548 shares. On January 22, 2026, he sold 1,421 common shares at a price of $93.3252 per share, leaving him with 42,127 common shares held directly. The filing notes that these shares were sold to cover tax withholding obligations tied to the vesting of the restricted stock units. Following the transactions, he also directly holds 6,666 restricted stock units, each representing the right to receive one share of common stock or its cash equivalent, with one-third of the award vesting annually from January 21, 2025 through the third anniversary.
Mirum Pharmaceuticals, Inc. executive Peter Radovich, the company’s President and COO, reported routine equity compensation activity. On January 21, 2026, 4,167 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0 per share. Each restricted stock unit represents a right to receive one share of common stock or its cash equivalent. Following this conversion, he held 23,061 shares of common stock, which includes 222 shares acquired under the company’s employee stock purchase plan.
On January 22, 2026, Radovich sold 2,382 shares of Mirum common stock at an average price of $93.3252 per share, with the shares sold to cover tax withholding obligations related to the RSU vesting. After the sale, he beneficially owned 20,679 shares of common stock directly, and 8,333 restricted stock units remained outstanding, scheduled to vest in equal annual installments through the third anniversary of January 21, 2025.
Mirum Pharmaceuticals, Inc. chief executive officer Christopher Peetz reported routine equity compensation activity and a related share sale. On January 21, 2026, 12,797 shares of common stock were acquired upon the vesting and settlement of restricted stock units, increasing his directly held common stock to 170,831 shares and his directly held restricted stock units to 25,593 units. On January 22, 2026, he sold 7,098 shares of common stock at $93.3252 per share, and the filing states these shares were sold to cover tax withholding obligations from the RSU vesting. After these transactions, he directly owns 163,733 shares of common stock and indirectly holds 187,500 shares of common stock through The Peetz Family Trust, in addition to the outstanding restricted stock units.
Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, reported equity award activity and a related share sale. On January 16, 2026, 12,500 restricted stock units vested and were converted into 12,500 shares of Mirum common stock at an exercise price of $0. Footnotes state that each unit represents one share and that one-third of the award vests on each anniversary of January 16, 2024 until fully vested after three years.
On January 20, 2026, Quan sold 6,911 shares of common stock at an average price of $90.2696 per share to cover tax withholding obligations tied to the vesting. After these transactions, she directly owned 11,305 shares of Mirum common stock and 12,500 restricted stock units.
Mirum Pharmaceuticals director Saira Ramasastry reported an option exercise and share sale in Mirum Pharmaceuticals, Inc. common stock. On January 15, 2026, she exercised a stock option for 2,000 shares of common stock at an exercise price of $23.51 per share and acquired 2,000 shares directly. That same day, she sold 2,000 shares of common stock at a price of $90.99 per share, leaving her with 0 shares of common stock held directly after the transactions.
The filing shows that the underlying stock option is fully vested and that 8,000 stock options remained beneficially owned following the reported activity. The sale was made pursuant to a Rule 10b5-1 trading plan that she adopted on September 18, 2025, indicating the transactions were carried out under a pre-established, automatic plan.